LAKE MARY, Fla., April 13 – Renewable fuels provider New Generation Biofuels Holdings, Inc. (NASDAQ: NGBF) (“New Generation Biofuels” or the “Company”) today announced that the Company produced and delivered a truckload sale of 5,000 gallons to Taunton State Hospital from its commercial-scale facility in Baltimore, Maryland as part of an existing sales order with the hospital signed in October 2008.
New Generation Biofuels also announced that it delivered its second truckload shipment to Delta Chemicals this week. Both deliveries are part of existing sales orders and will contribute to a total of 45,000 gallons of biofuel scheduled to be delivered to New Generation Biofuels’ customers in April.
“These shipments demonstrate our progress in producing and delivering on the sales contracts we have signed with key customers interested in using our renewable biofuel to lower their emissions and carbon footprints,” said Cary Claiborne, President, CEO and CFO of New Generation Biofuels. “Since February we completed construction of our facility in Baltimore, secured new customers, delivered our product, completed successful test burns, expanded our licensing agreement and raised additional funds. We are very pleased with these recent accomplishments and look forward to building on this positive momentum as we continue to execute our new business plan,” Claiborne added.
About New Generation Biofuels, Holdings, Inc.
New Generation Biofuels is a renewable fuels provider. New Generation Biofuels holds an exclusive license for North America, Central America and the Caribbean to commercialize proprietary technology to manufacture alternative biofuels from vegetable oils and animal fats that it markets as a new class of biofuel for power generation, commercial and industrial heating and marine use. The Company believes that its proprietary biofuel can provide a lower cost, renewable alternative energy source with significantly lower emissions than traditional fuels. New Generation Biofuels’ business model calls for establishing direct sales from manufacturing plants that it may purchase or build and sublicensing its technology to qualified licensees.